Heron Therapeutics (HRTX) Retained Earnings: 2010-2025
Historic Retained Earnings for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to -$1.9 billion.
- Heron Therapeutics' Retained Earnings fell 0.71% to -$1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 billion, marking a year-over-year decrease of 0.71%. This contributed to the annual value of -$1.9 billion for FY2024, which is 0.71% down from last year.
- Per Heron Therapeutics' latest filing, its Retained Earnings stood at -$1.9 billion for Q3 2025, which was down 0.91% from -$1.9 billion recorded in Q2 2025.
- Heron Therapeutics' Retained Earnings' 5-year high stood at -$1.4 billion during Q1 2021, with a 5-year trough of -$1.9 billion in Q3 2025.
- Its 3-year average for Retained Earnings is -$1.9 billion, with a median of -$1.9 billion in 2025.
- Data for Heron Therapeutics' Retained Earnings shows a maximum YoY dropped of 18.76% (in 2021) over the last 5 years.
- Over the past 5 years, Heron Therapeutics' Retained Earnings (Quarterly) stood at -$1.6 billion in 2021, then decreased by 11.28% to -$1.8 billion in 2022, then dropped by 6.16% to -$1.9 billion in 2023, then declined by 0.71% to -$1.9 billion in 2024, then dropped by 0.71% to -$1.9 billion in 2025.
- Its Retained Earnings stands at -$1.9 billion for Q3 2025, versus -$1.9 billion for Q2 2025 and -$1.9 billion for Q1 2025.